The proto-oncogene ROS1 encodes a receptor tyrosine kinase with an unknown
physiological role in humans. Somatic chromosomal fusions involving ROS1 produce …

The ROS-1 gene plays a major role in the oncogenesis of numerous tumors. ROS-1
rearrangement is found in 0.9–2.6% of non-small-cell lung cancers (NSCLCs), mostly lung …

Background Gene fusions represent promising targets for cancer therapy in lung cancer.
Reliable detection of multiple gene fusions is therefore essential. Methods Five …

Since the discovery of echinoderm microtubule-associated protein-like 4 (EML4) and
anaplastic lymphoma kinase (ALK) gene fusion in non-small cell lung carcinoma (NSCLC) …

Introduction Variable genomic breakpoints have been identified through the application of
target-capture DNA next-generation sequencing (NGS) for ALK, ROS1, and RET fusion …

Introduction Central nervous system (CNS) metastases in lung cancer are a frequent cause
of morbidity and mortality. There are conflicting data on the incidence of CNS metastases in …

Non─ small cell lung cancer (NSCLC) presents different druggable genetic abnormalities,
including ROS1 and ALK rearrangements, which share relevant clinical features and …

Introduction ROS1 rearrangements are found in 1% of lung cancer patients. Therapeutic
efficacy of crizotinib in this subset has been shown in early phase trials in the United States …

Tyrosine kinase inhibitors currently confer the greatest survival gain for nonsmall cell lung
cancer (NSCLC) patients with actionable genetic alterations. Simultaneously, the increasing …

Abstract Purpose of Review Molecular drivers are increasingly identified as therapeutic
targets for non-small cell lung cancer (NSCLC). This review focuses on the role of ROS1 …